DE · HAEK.DE
Haemato AG
Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….
Price · as of 2026-10-09
$21.40
Market cap 111.5M
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for Haemato AG (HAEK.DE) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About Haemato AG
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European imported drugs and medical products; and manufactures and distributes its generic drugs. It provides pharmaceuticals in the areas of oncology, HIV, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic medicine, as well as cosmetic products. The company also develops and markets medical devices and medical technology products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors, clinics, and medical laboratories. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.
- CEO
- Patrick Brenske
- Employees
- 76
- Beta
- 1.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.